These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35962212)

  • 1. Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.
    Pe J; Choi B; Choi H; Kwon SW; Kim DH
    Cardiovasc Intervent Radiol; 2022 Dec; 45(12):1834-1841. PubMed ID: 35962212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma.
    Park W; Cho S; Ji J; Lewandowski RJ; Larson AC; Kim DH
    Radiol Imaging Cancer; 2021 Jan; 3(1):e200006. PubMed ID: 33575658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
    Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium Cholate Bile Acid-Stabilized Ferumoxytol-Doxorubicin-Lipiodol Emulsion for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.
    Kwak K; Yu B; Mouli SK; Larson AC; Kim DH
    J Vasc Interv Radiol; 2020 Oct; 31(10):1697-1705.e3. PubMed ID: 32773247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
    Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
    Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer.
    Liu L; Liang X; Xu X; Zhang X; Wen J; Chen K; Su X; Teng Z; Lu G; Xu J
    Acta Biomater; 2021 Aug; 130():374-384. PubMed ID: 34082098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
    Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
    AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo-Immuno-Embolization for the Treatment of Hepatocellular Carcinoma.
    Kim H; Choi B; Mouli SK; Choi H; Harris KR; Kulik LM; Lewandowski RJ; Kim DH
    Adv Healthc Mater; 2023 Oct; 12(26):e2300906. PubMed ID: 37163283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 14. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
    Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
    Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.
    Nouri YM; Kim JH; Yoon HK; Ko HK; Shin JH; Gwon DI
    Korean J Radiol; 2019 Jan; 20(1):34-49. PubMed ID: 30627020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
    Kuroda H; Oikawa T; Ninomiya M; Fujita M; Abe K; Okumoto K; Katsumi T; Sato W; Igarashi G; Iino C; Endo T; Tanabe N; Numao H; Fukuda S; Iijima K; Masamune A; Ohira H; Ueno Y; Takikawa Y
    Liver Cancer; 2022 Jul; 11(4):383-396. PubMed ID: 35978602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort.
    Sandow TA; Arndt SE; Albar AA; DeVun DA; Kirsch DS; Gimenez JM; Bohorquez HE; Gilbert PJ; Thevenot PT; Nunez KG; Galliano GA; Cohen AJ; Kay D; Gulotta PM
    Radiology; 2018 Mar; 286(3):1072-1083. PubMed ID: 29206595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
    Xia X; Li X; Feng G; Zheng C; Liang H; Zhou G
    Acta Radiol; 2013 Jul; 54(6):684-9. PubMed ID: 23507934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.